Results 231 to 240 of about 15,269 (294)

Cytotoxic lymphocytes counteract viral type I interferon immune evasion. [PDF]

open access: yesPLoS Pathog
Schakelaar MY   +10 more
europepmc   +1 more source

Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK‐positive anaplastic large‐cell lymphoma

open access: yesHistopathology, Volume 89, Issue 6, Page 1031-1041, December 2026.
Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin   +6 more
wiley   +1 more source

Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy? [PDF]

open access: yesJ Immunother Cancer
van Wandeloo IMB   +4 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

open access: yesImmunology, Volume 179, Issue 4, Page 579-593, December 2026.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia   +10 more
wiley   +1 more source

The effect of COVID-19 and sex differences on natural killer cell cytotoxicity. [PDF]

open access: yesFront Cell Infect Microbiol
Dagar A   +6 more
europepmc   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

open access: yesCancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato   +5 more
wiley   +1 more source

Granzyme A amplifies human neutrophil pyroptosis

open access: yes
Kasperkiewicz P   +15 more
europepmc   +1 more source

Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. [PDF]

open access: yesAnn Med Surg (Lond)
Ali H   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy